Epilepsy clinical trials in Alabama
9 studies for Epilepsy are looking for participants at sites in Alabama.
Cities in Alabama
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
- UAB Epilepsy Center, Birmingham
RecruitingObservational study
Ages 18 to 75 · All sexes · Updated Sep 15, 2026 · NCT07110454Diagnosing Epilepsy To EffeCT Change
- UAB Epilepsy Center, Birmingham
Recruiting
Ages 18 to 75 · All sexes · Updated Sep 15, 2026 · NCT07110337Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
- Clinic for Neurology, Huntsville
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 2, 2026 · NCT07594119AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Aug 24, 2026 · NCT06063850A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
- University of Alabama - Strada Patient Care Center, Neurology, Mobile
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Aug 10, 2026 · NCT05667142Stimulation-Induced Changes in Fronto-Limbic Network
- Epilepsy Monitoring Unit UAB Hospital, Birmingham
Recruiting
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT05854160Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
- University of Alabama, Birmingham
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Jun 9, 2026 · NCT05135091Investigating Dynamic Interactions in Distributed Cognitive Control Networks
- University of Alabama at Birmingham, Birmingham
RecruitingObservational study
Ages 18 and older · All sexes · Updated Apr 29, 2026 · NCT05927974Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 2
1 Day – 6 Months · All sexes · Updated Jan 22, 2026 · NCT05104983From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.